AUCTORES
Globalize your Research
Research Article | DOI: https://doi.org/10.31579/2690-4861/417
Department of Laboratory, The First People's Hospital of Yunnan Province, Affiliated Hospital of Kunming University of Science and Technology, Kunming 650032, Yunnan Province, China
*Corresponding Author: Rui Tao, Department of Laboratory, The First People's Hospital of Yunnan Province, Affiliated Hospital of Kunming University of Science and Technology, Kunming 650032, Yunnan Province, China.
Citation: Min Tang, Na Li, Jinhua Dao, Jianqiong Wang, Rui Tao, et al, (2024), Combination of Chinese and Western Medicine: Molnupiravir and Lianhua Qingwen in the Treatment of Novel Coronavirus Pneumonia (COVID-19), International Journal of Clinical Case Reports and Reviews, 16(5); DOI:10.31579/2690-4861/417
Copyright: © 2024, Rui Tao. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Received: 10 March 2024 | Accepted: 18 March 2024 | Published: 26 March 2024
Keywords: novel coronavirus; Molnupiravir; Lianhua Qingdao; viral load
Objective: This study aimed to assess the effectiveness of Molnupiravir and Lianhua Qingwen in treating patients with novel coronavirus pneumonia (COVID-19).
Materials and Methods: We conducted a study involving 14 cases of COVID-19 infection within a unit group in Laos. During the treatment regimen, these patients received the antiviral drugs Molnupiravir and Lianhua Qingwen as prescribed. We utilized laboratory results of viral nucleic acid tests as observational parameters and statistically analyzed the data using SPSS 26.0 software (linear regression analysis). Our data analysis aimed to determine if there were significant differences in the Ct values of the N gene and ORF1ab gene of SARS-CoV-2 before and after treatment.
Results: The results indicated statistically significant differences in the N gene (t =﹣7.014, P < 0.001) and ORF1ab gene (t =﹣7.398, P < 0.001). Post-treatment, the values of the N gene and ORF1ab gene were significantly higher than their pre-treatment values, signifying that the combined utilization of Molnupiravir and Lianhua Qingwen had a substantial impact on the treatment of COVID-19.
Conclusion: Molnupiravir and Lianhua Qingwen effectively inhibited the replication of SARS-CoV-2, resulting in a marked improvement in the clinical symptoms of the patients. Laboratory test results also indicated a significant reduction in viral load. These findings provide substantial evidence supporting the efficacy of the combination of Molnupiravir and Lianhua Qingwen in the treatment of COVID-19.
Since December 2019, the world has been grappling with an outbreak of novel coronavirus pneumonia, known as Coronavirus Disease 2019 (COVID-19), originating in Wuhan, Hubei Province, China. This outbreak soon spread to numerous countries worldwide[1]. The gravity of the situation prompted the World Health Organization
(WHO) to declare the COVID-19 outbreak a Public Health Emergency of International Concern (PHEIC) on January 30, 2020. Subsequently, on March 11, 2020, WHO escalated its classification to declare COVID-19 a global pandemic[2]. As of December 2022, the disease has caused approximately 6.6 million deaths and over 651 million infections[3].
Consequently, in addition to the extensive efforts directed toward the development and promotion of antiviral vaccines, nations have been actively engaged in the development of various antiviral drugs. In November 2021, the UK Medicines and Healthcare Products Regulatory Authority (MHRA) approved the launch of the antiviral drug Molnupiravir[4]. The efficacy of Molnupiravir in reducing hospitalization and death rates among COVID-19 patients has been demonstrated in clinical trials, with a reduction of up to 50% in risk[5].
Lianhua Qingwen is an innovative patented traditional Chinese medicine with potential efficacy against respiratory system diseases[6]. It can alleviate symptoms such as fever, cough, fatigue, muscle pain, and shortness of breath[7]. This traditional Chinese medicine is used to prevent severe acute respiratory syndrome (SARS)[8] and can inhibit and kill coronaviruses associated with SARS and Middle East respiratory syndrome[9-11]. Over the past decade, it has become a representative traditional Chinese medicine for treating respiratory infectious diseases[12].
This article aims to explore the potential efficacy of the newly approved antiviral drug Monupiravir in combination with the traditional Chinese medicine Lianhua Qingwen in the treatment of COVID-19. By investigating the combined use of these treatment methods, this study aims to help understand the effective treatment methods of COVID-19 and may provide new insights and strategies for combating the epidemic.
1 Information and Methodology
1.1 Subjects We enrolled a total of 14 COVID-19-infected patients from a specific unit group in April 2022 for this study. Among these participants, there were 12 male patients and 2 female patients, ranging in age from 27 to 57 years. In this study, we employed a random sampling method to ensure the representativeness of our sample. This approach aims to randomly select research subjects from the entire population rather than targeting specific individuals or groups. The purpose of our adoption of random sampling is to enhance the generalizability and comparability of the study results, thereby increasing the reliability and credibility of our research. The diagnosis of COVID-19 in these patients adhered to the criteria outlined in the "Diagnostic and Treatment Program for Novel Coronavirus Pneumonia (Trial Ninth Edition).[13]" It is worth noting that these patients did not have any specific records or events related to a history of infection-like illnesses. Consequently.
1.2 Methods The patients received a prescribed course of medication following the instructions for Molnupiravir and the guidance provided in the "Diagnostic and Treatment Program for Novel Coronavirus Pneumonia (Trial Ninth Edition)." During the study, we performed SARS-CoV-2 nucleic acid testing on infected patients, which included testing for the ORF1ab and N genes. Testing was conducted during two stages: the initial stage of infection (prior to treatment initiation) and during the treatment period (after completing the first course of treatment). Corresponding Ct values were recorded at both stages.
1.3 Reagents and Instruments
1.3.1 Sample Collection: For sample collection, single-use virus sampling tubes containing guanidinium salts were employed. Both nasal and pharyngeal areas were simultaneously sampled in this study[13-15].
1.3.2 In this study, a series of nucleic acid extraction devices and reagents were employed. The nucleic acid extraction apparatus used was an automatic nucleic acid extractor, and the nucleic acid extraction reagent utilized was a commercially available kit. For nucleic acid amplification, a fully automated medical PCR analysis system was utilized alongside a commercially available nucleic acid amplification reagent.
1.3.3 Procedure: We strictly adhere to the protocols provided by the experimental instruments and reagents. The procedure begins by equilibrating the nucleic acid amplification reaction solution, enzyme mixture, and ORF1ab/N reaction solution from the kit to room temperature. Subsequently, these components are briefly centrifuged with full shaking, and a reaction system with a total volume of 20 μL is prepared. Purification and nucleic acid extraction are conducted using the nucleic acid amplification instrument, employing 200 μL of the sample and nucleic acid extraction reagent. Following this, 5 μL of the purified sample is added to the reaction system, which is then briefly centrifuged with tightly fitted caps. For each batch of experiments, including 3 negative controls and 1 positive control is essential. Reverse transcription is performed at 50℃ for 10 minutes, followed by pre-denaturation at 95℃ for 5 minutes, denaturation at 95℃ for 10 seconds, and annealing/extension/detection of fluorescence at 55℃ for 40 seconds, with a total of 45 cycles.
1.3.4 Methodology: In this study, real-time fluorescence PCR was employed, with specially designed primers for the ORF1ab and N genes of SARS-CoV-2, along with TaqMan probes[16]. These were amplified using a fluorescence quantitative PCR instrument. We used the ROC curve method to determine the CT values for the ORF1ab and N genes. To ensure experiment accuracy, we incorporated endogenous ribonuclease P (RNase P) as an internal reference control[17]. This was done to monitor the experiment throughout the process and prevent false-negative results resulting from misclassification.
1.3.5 Quality Control: Each batch of experiments must adhere to the requirements outlined in Table 1 for both negative and positive controls. Additionally, the Ct value of the RNase P assay for human samples should be less than 45, ensuring the quality of the experiment[17].
| target of detection | negative control | positive control |
| ORF1ab | No Ct value | Ct ≤ 30 |
| N | No Ct value | Ct ≤ 30 |
| internal reference (within the same publication) | — | Ct ≤ 30 |
Table 1: Negative/positive control Ct value
The data were analyzed statistically using SPSS 26.0 software. A linear regression analysis was conducted to examine the Ct values of the N gene and ORF1ab gene before and after treatment. The statistical results are presented in Table 2. The significance of the difference in Ct values between the N gene and ORF1ab gene before and after processing was determined based on the data analysis. A significance level of p < 0>
| serial number | gender | age | Pre- treatment | Post-treatment | ||
| N | ORF1ab | N | ORF1ab | |||
| 1 | male | 33 | 18.285 | 18.043 | 34.371 | 36.348 |
| 2 | female | 32 | 28.246 | 28.363 | 41.000 | 41.000 |
| 3 | male | 40 | 26.887 | 27.605 | 41.000 | 41.000 |
| 4 | male | 27 | 23.457 | 23.121 | 31.973 | 33.160 |
| 5 | male | 38 | 22.238 | 22.598 | 41.000 | 41.000 |
| 6 | female | 32 | 28.629 | 28.832 | 37.543 | 41.000 |
| 7 | Man | 39 | 22.137 | 23.371 | 37.988 | 41.000 |
| 8 | Man | 48 | 37.098 | 38.902 | 41.000 | 41.000 |
| 9 | Man | 38 | 31.902 | 32.637 | 36.887 | 41.000 |
| 10 | Man | 42 | 26.410 | 26.379 | 34.316 | 33.590 |
| 11 | male | 45 | 20.801 | 19.793 | 41.000 | 39.863 |
| 12 | male | 45 | 18.348 | 18.004 | 41.000 | 40.238 |
| 13 | male | 57 | 14.980 | 15.645 | 25.234 | 24.199 |
| 14 | male | 50 | 19.035 | 20.066 | 41.000 | 41.000 |
Table 2: Case data statistics
The statistical results presented in Table 3 reveal significant differences in the N gene (t =﹣7.014, P < 0 t =﹣7.398,> Pre-treatment Post-treatment t P M SD M SD N 24.175 6.044 37.138 4.614 ﹣7.014 0.000 ORF1ab 24.526 6.393 37.921 4.881 ﹣7.398 0.000
Table 3: Differential comparison of treatment effects before and after treatment
Currently, the Omicron strain has replaced the Delta strain as the predominantly endemic strain[18, 19]. Although the Omicron strain is more transmissible than the Delta strain, its pathogenicity has diminished[20]. In our study, we observed that many cases infected with the Omicron strain did not exhibit significant clinical symptoms. Patients only displayed mild to moderate respiratory and systemic symptoms and did not develop hypoxia, shortness of breath, or other complications necessitating hospitalization. In our clinical laboratory, we employ PCR to detect SARS-CoV-2 viral load. Studies, such as the work of E. Pujadas and others have established an association between SARS-CoV-2 viral load and mortality[21]. Our research primarily focused on patients in the early stages of the disease when the virus was actively replicating, and our findings indicated that outpatient antiviral therapy could effectively halt disease progression, reducing hospitalization and mortality rates[22].
Molnupiravir, an oral antiviral drug has demonstrated efficacy in treating patients with early-stage, mild cases of COVID-19[23]. It recently completed Phase III clinical trials in late 2021 and was approved for use in late 2022. The UK was the first country to authorize the use of Molnupiravir[4]. Some researchers, like F. Kabinger et al., have noted that Molnupiravir's mechanism of action includes increasing the frequency of viral RNA mutations and impairing SARS-CoV-2 replication in both animal models and humans[24].
This aligns with our findings, as we observed a decline in Ct values of SARS-CoV-2 nucleic acid assay results after two courses of the drug, suggesting a reduction in viral load. Our findings supported the discontinuation of centralized isolation, as per the newly released "Diagnostic and Treatment Protocol for Novel Coronavirus Pneumonia (Trial 10th Edition).[13]"
Lianhua Qingwen is an innovative and patented herbal medicine with potential efficacy in treating respiratory diseases[6]. In COVID-19 treatment, Lianhua Qingwen has demonstrated favorable therapeutic effects with minimal adverse reactions[25]. It was included in the "New Coronavirus Pneumonia Diagnosis and Treatment Program (Trial Ninth Edition)" issued by the National Health Commission in March 2022 as a therapeutic drug for patients with medically observed, mild, and common forms of the disease[13-26]. Recent studies, such as those by Chen Chaowu[27], Tan Duxun[28], and Li Ya[29], have confirmed its effectiveness in improving clinical symptoms and reducing inflammation in patients. additionally, research by Liu M and others[30] suggests that combining Chinese and Western medicine is more effective in treating COVID-19 without increasing adverse effects.
Molnupiravir, as a ribonucleoside analog, can inhibit the replication of the coronavirus[31]. When combined with Lianhua Qingwen in our study, it effectively reduced viral load in patients, as evidenced by declining Ct values. However, as a drug that recently completed clinical phase III trials, its efficacy and potential side effects in treating COVID-19 require further scientific investigation. Scholars, such as R. Dal-Ré, emphasize the importance of assessing the safety and efficacy of antiviral medications against the Omicron variant[32]. Furthermore, the active metabolite of Molnupiravir, β-d-n4-hydroxy cytidine, has been reported to be cytotoxic and mutagenic in mammalian cells[24-33]. The use of Molnupiravir has drawn significant attention, and more research is needed to comprehensively assess its efficacy and safety in combination therapy.
Limitation of the Study
Our study focuses on the limited research regarding the combined application of Molnupiravir and Lianhua Qingwen in integrative Chinese and Western medicine treatment for COVID-19, employing rigorous research design, implementation, and data analysis methods. It represents a unique and innovative contribution, filling a gap in the literature and providing insights into the combined treatment of COVID-19 using Molnupiravir and Lianhua Qingwen. While our study is preliminary and exploratory, aiming to lay the groundwork for future larger-scale research, it offers valuable insights for clinical practice.
Our research sheds light on COVID-19 treatment, particularly in the early stages of infection. The combined therapy of Molnupiravir and Lianhua Qingwen shows promising clinical benefits, contributing to epidemic control and patient well-being. However, further scientific validation is required to confirm the efficacy and safety of these treatments in clinical settings. Multi-center clinical trials should be strengthened to fully explore their potential in addressing the evolving landscape of COVID-19 and safeguarding global public health.
The potential of Molnupiravir in treating COVID-19 has attracted significant attention, with some promising research findings. However, further comprehensive scientific investigation is necessary to evaluate its efficacy and safety, particularly in combination therapy. Our study reinforces the promising performance of Molnupiravir in treating COVID-19 patients, aligning with prior research and offering valuable insights into reducing viral load, facilitating patient recovery, and enhancing the drug's clinical application. Similarly, Lianhua Qingwen, an innovative traditional Chinese medicine, has emerged as a promising tool in combating COVID-19, demonstrating efficacy in symptom improvement and modulating the body's response, particularly in early treatment. The growing recognition of the importance of integrating Chinese and Western medicine is evident among scholars, and our study provides a novel perspective, especially for early-stage infections. The combination therapy of Molnupiravir and Lianhua Qingwen presents potential clinical benefits and significantly contributes to epidemic control and patient well-being.
In this study, we have substantiated the efficacy of Molnupiravir and Lianhua Qingwen in effectively inhibiting the replication of SARS-CoV-2. This provides robust and compelling evidence of their effectiveness.
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.
Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.
Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.
We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.
The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.
Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.
Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.
Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.
Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.
Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.
This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.
Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.
As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.
Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.
International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.
Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.
Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.
I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!
"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".
I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.
We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.
I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.
I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.
I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.
Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.
“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.
Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.
Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.
Clinical Cardiology and Cardiovascular Interventions, we deeply appreciate the interest shown in our work and its publication. It has been a true pleasure to collaborate with you. The peer review process, as well as the support provided by the editorial office, have been exceptional, and the quality of the journal is very high, which was a determining factor in our decision to publish with you.
The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews journal clinically in the future time.
Clinical Cardiology and Cardiovascular Interventions, I would like to express my sincerest gratitude for the trust placed in our team for the publication in your journal. It has been a true pleasure to collaborate with you on this project. I am pleased to inform you that both the peer review process and the attention from the editorial coordination have been excellent. Your team has worked with dedication and professionalism to ensure that your publication meets the highest standards of quality. We are confident that this collaboration will result in mutual success, and we are eager to see the fruits of this shared effort.
